#Israel #CollPlant #rhCollagen #Rehovot #Bioink

CollPlant Biotechnologies Reports Third Quarter 2025 Financial Results

On November 26, 2025, CollPlant Biotechnologies, a leader in regenerative and aesthetic medicine, unveiled its financial outcomes for the third quarter of 2025, alongside crucial corporate updates. The company experienced a notable expansion in the sales of its rhCollagen and BioInk products, largely attributed to a recent partnership with a U.S.-based logistics center that is set to enhance its distribution capabilities across North America.

Financial Highlights and Sales Growth

CollPlant reported a significant revenue surge in the third quarter, with revenues reaching $77,000 compared to a mere $4,000 in the same period of 2024. This impressive increase is largely due to heightened sales of rhCollagen-based products, which also contributed to a total revenue of $2.3 million for the first nine months of 2025. This new financial landscape further emphasizes the effectiveness of CollPlant's strategic initiatives aimed at expanding its market reach.

Innovations in Medical Aesthetics

CollPlant is paving the way for innovations in medical aesthetics through continual advancements in its dermal filler program. CEO Yehiel Tal highlighted the groundbreaking work achieved at the Mayo Clinic, where researchers developed a fully humanized 3D bioprinted skin model utilizing CollPlant's rhCollagen. This model demonstrates potential as a viable alternative to animal testing, aligning with the company's strong commitment to ethical research practices.

Furthermore, research conducted at Technion - Israel Institute of Technology revealed that CollPlant’s advanced bioink, Collink.3D™, surpasses Matrigel® in tissue structure support. This means our technology provides a consistent and tunable, non-animal option for advanced research endeavors, thus offering a sustainable path forward in tissue engineering with an expanding market estimated to be worth around $100 million.

Cost Management and Strategic Priorities

To maintain its financial health amid growth, CollPlant has implemented a cost-reduction strategy alongside an initiative for program prioritization. These changes are expected to extend the cash runway and ensure a robust foundation for future projects. Plans indicate that CollPlant may reduce its workforce by approximately 25%, aiming to streamline operations without sacrificing innovation.

Partnership with AbbVie

In line with CollPlant's strategic expansion, the company received a $2 million milestone payment from AbbVie earlier this year, which marked a major achievement in their partnership agreement to commercialize dermal fillers combining CollPlant’s proprietary rhCollagen technology. This partnership reinforces CollPlant's position in the market and promises to deliver superior products by leveraging state-of-the-art technologies.

Upcoming Opportunities and Forward Outlook

As CollPlant prepares for its clinical phase dermal filler candidates and continues to explore the commercial viability of its photocurable dermal filler program, the company remains optimistic about future growth opportunities. The logistics facility in North America is expected to enhance the distribution efficiency for its rhCollagen and BioInk products, which are seen as pivotal to the company's success.

As these initiatives unfold, stakeholders can anticipate continual updates on CollPlant’s progress as it actively seeks strategic partnerships and enhances its offerings in regenerative medicine and aesthetics. The commitment to innovation, ethical practices, and consumer satisfaction remains at the forefront of CollPlant’s business objectives as it enters the next stage of growth for the next year.